News and Comments

WOULD YOU BET ON GALENA BIOPHARMA NEUVAX VACCINE NOW?

  Thursday, June 12, 2014

 More...

ARRAY GOOD NEWS AND BIOCRYST OFFERING

  Wednesday, May 28, 2014

ARRAY (ARRY) More...

INTERMUNE OFFERS COMPASSIONATE TREATMENT FOR PATIENTS WITH IDEOPATHIC PULMONARY FIBROSIS V

  Friday, May 16, 2014

 More...

A NEW MUCH IMPROVED AGENUS?

  Tuesday, April 29, 2014

In February 2014 Agenus (AGEN) acquired 4-Antibody and with it its breakthrough Retrocyte Display technology. Two months later, Agenus signed a collaboration and license agreement with Merck, for the discovery and development of therapeutic antibodies to immune checkpoints for the treatment of cancer through the newly acquired Retrocyte Display technology.  More...

GILEAD SOVALDI IS THE SOLUTION NOT THE PROBLEM

  Monday, April 28, 2014

Why sell side investors select to short outperforming firms when they know they are betting against growth firms expected to announce extraordinarily positive game changing news?    More...

CYTOKINETICS: THE MOMENT OF HALF THE TRUTH

  Friday, April 25, 2014

Bad news has come from Cytokinetics' (CYTK) top-line results of BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). Bottom line, BENEFIT-ALS trial did not achieve its primary efficacy endpoint, the mean change from baseline in the ALS Functional Rating Scale in its revised form (ALSFRS-R) on tirasemtiv versus placebo (-2.98 points in the tirasemtiv group versus -2.40 points in the placebo group, p = 0.11). Another ambitious attempt to decrease some of ALS burden on the sufferers has disappointed.  
 More...

AGEN: IRRATIONAL REACTION AGAINST EXPECTED NEWS

  Thursday, March 20, 2014
 More...

PROSENSA: BACK INTO THE LIMELIGHT

  Tuesday, March 18, 2014

Prosensa Holding N.V. (RNA) might have good news that was made possible through insightful observation following past results that almost condemned the Dutch biopharmaceutical company’s compound drisapersen for the treatment of Duchenne Muscular Dystrophy (DMD).  More...

JAKAFI DEVELOPED BY INCYTE MET THE PRIMARY ENDPOINTS FOR POLYCYTHEMIA VERA

  Friday, March 07, 2014

Incyte (INCY) announced results from pivotal Phase 3 trial of Jakafi (ruxolitinib) in polycythemia vera patients who are resistant to or intolerant of hydroxyurea. The results met the primary endpoints; achieving phlebotomy independence and reducing spleen size by 35 percent or more compared to best available therapy.  More...

INCYTE: SHOWS ITS PATH TOWARDS GROWTH

  Wednesday, February 12, 2014

 More...


Recent News_and_Comments


Archive


Tags